Tag Archives: Boehringer Ingelheim

Boehringer Ingelheim increases commitments to sustainable development, to impact 50 million people through social innovation

Boehringer Ingelheim increases commitments to sustainable development, to impact 50 million people through social innovation

Boehringer Ingelheim marks One Health Day 2021 by evolving commitments to sustainable development relating to the company’s employees, partners, and communities Updates include expanding healthcare access for non-communicable diseases for 50 million people in vulnerable communities, and an additional 50 million people reached through engagement and social entrepreneurship Ingelheim, 11 November 2021 – On the

Boehringer Ingelheim shares updated 2030 environmental sustainability commitments

Boehringer Ingelheim marks COP26 by announcing updates to its strategic approach to sustainable development The company commits to becoming carbon neutral in company operations by 2030 and further reducing the overall water footprint, operational waste to landfill and resource use Boehringer Ingelheim implements ambitious internal carbon price of EUR 100 per ton CO2 emissions to

Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030

• Boehringer Ingelheim marks the World Health Summit 2021 by announcing updates to its strategic approach to sustainable development • The company commits to investing EUR 250 million in collaborations to combat infectious diseases in humans and animals, and increases investment in health innovation and research to tackle non-communicable diseases worldwide • In addition, Boehringer

Landmark trial, EMPEROR-Preserved, demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

In this clinical study for adults with heart failure with preserved ejection fraction, empagliflozin demonstrated an impressive 21 percent relative risk reduction in the composite primary endpoint of cardiovascular death or hospitalization for heart failure[1] The benefit in the primary endpoint was independent of ejection fraction or diabetes status1 Empagliflozin also reduced the relative risk

Leading Healthcare Experts Highlight Importance of Multidisciplinary Treatment Approach at ‘2021 Regional Interchange on Diabetes’

Over 300 nephrologists, endocrinologists, internists, diabetologists and cardiologists from across the Middle East and Africa met at the two-day conference organized by Boehringer Ingelheim The interconnected nature of cardio, renal and metabolic systems require a multidisciplinary approach to manage and treat patients with type 2 diabetes as an underlying risk factor Cardio-renal-metabolic (‘CRM’) conditions are

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Strong R&D commitment to developing therapeutics against SARS-CoV-2 virus Overall R&D investment up 7% to 3.7 billion EUR in 2020 (18.9% of net sales) Positive business performance despite the impact of COVID-19 pandemic Total human pharmaceuticals and animal health net sales in 2020 across the Middle East, Turkey, and Africa witnessed 11% growth , Boehringer

Boehringer Ingelheim Recognized As Global Top Employer for 2021

Boehringer Ingelheim has been recognized as one of the 16 Top Employers Worldwide by the Top Employers Institute for its long-term strategic orientation, modern management culture and strong employee communication practices    ‘Top Employer’ recognition awarded to Boehringer Ingelheim Saudi Arabia for its strong employee culture, development and support programs In total, 27 Boehringer Ingelheim

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 percent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin also significantly reduced the relative risk of first and recurrent hospitalization for heart failure by 30 percent and significantly slowed kidney function decline[i] Results were consistent in subgroups with and without type 2 diabetes1 Heart failure is the leading cause of hospitalization in the U.S. and Europe[ii] Results from the Phase III EMPEROR-Reduced trial

Boehringer Ingelheim Launches New Arabic Website to Support Patients Living with Idiopathic Pulmonary Fibrosis in the Region

Sixty million people across the Middle East may be at risk of developing respiratory illnesses such as pulmonary fibrosis [1] Marking IPF Awareness Week, the launch of Boehringer Ingelheim’s new website aims to address the current gap in credible resources and information in the Arabic language and to support patients and caregivers across the region

Boehringer Ingelheim Teams Up with the Lebanese Pulmonary Society (LPS) in its Fight against COVID-19

Boehringer Ingelheim‘s Global Support Program aiming at bringing more financial relief to the countries in need Donation allocated to the Lebanese Pulmonary Society (LPS) worth of medical supplies The donation included surgical face masks, sanitizers, gloves, oximeters, infra-thermometers, face shields and N-95 masks Beirut, 11th of June 2020 – In joining the fight to reduce the